MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
65.68
+0.17
+0.26%
After Hours: 65.80 +0.12 +0.18% 19:30 09/11 EDT
OPEN
65.96
PREV CLOSE
65.51
HIGH
66.05
LOW
65.29
VOLUME
1.60M
TURNOVER
--
52 WEEK HIGH
70.98
52 WEEK LOW
49.26
MARKET CAP
12.71B
P/E (TTM)
177.08
1D
5D
1M
3M
1Y
5Y
1D
BioMarin Pharmaceutical (BMRN) Posts Phase 3 Win And FDA Filing In Hypochondroplasia
Simply Wall St · 1d ago
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
NASDAQ · 1d ago
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and BioMarin Pharmaceutical (BMRN)
TipRanks · 2d ago
Growth Without AI: 8 Stock Picks
Barron‘s · 2d ago
BioMarin: Neutral (Hold) Rating Reiterated as VOXZOGO Opportunity Balances YUVIWEL Competitive Risk; $60 Price Target Unchanged
TipRanks · 3d ago
BioMarin Pharmaceutical Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target
Benzinga · 3d ago
BioMarin's VOXZOGO Hits Phase 3 Growth Endpoint In Hypochondroplasia
NASDAQ · 3d ago
More
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene.

Webull offers Biomarin Pharmaceutical Inc stock information, including NASDAQ: BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.